| Not Yet Recruiting | BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) NCT05393466 | Xcovery Holdings, Inc. | Phase 1 / Phase 2 |
| Suspended | Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 NCT05642195 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Not Yet Recruiting | Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigen NCT06694454 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Retifanlimab and Ruxolitinib In Solid Malignancies NCT07219576 | University of California, San Diego | Phase 1 / Phase 2 |
| Recruiting | First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors NCT07284186 | Plexium, Inc. | Phase 1 |
| Recruiting | A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants NCT07144280 | Pfizer | Phase 3 |
| Recruiting | Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With NCT06772623 | AbbVie | Phase 1 / Phase 2 |
| Recruiting | Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT NCT06222489 | The Netherlands Cancer Institute | Phase 2 |
| Terminated | A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMAR NCT06560645 | Prelude Therapeutics | Phase 1 |
| Active Not Recruiting | Acupuncture for Enhancing Immunotherapy in Advanced NSCLC：a Pilot Study NCT06461338 | Guangzhou University of Traditional Chinese Medicine | N/A |
| Not Yet Recruiting | Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours NCT05698238 | Mabpro, a.s. | Phase 1 |
| Terminated | Study of IK-595 in RAS- or RAF-altered Advanced Tumors NCT06270082 | Ikena Oncology | Phase 1 |
| Unknown | Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI NCT05869162 | Shouyao Holdings (Beijing) Co. LTD | Phase 2 |
| Recruiting | A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea NCT05703516 | Novartis Pharmaceuticals | — |
| Active Not Recruiting | A Study to Compare Tissue and Liquid Biopsies in People With Different Types of Cancer NCT05708599 | Boehringer Ingelheim | N/A |
| Active Not Recruiting | Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutati NCT05358249 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC. NCT05110196 | Novartis Pharmaceuticals | Phase 4 |
| Recruiting | The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors NCT05037825 | VastBiome | — |
| Active Not Recruiting | NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastat NCT04984811 | NeoImmuneTech | Phase 2 |
| Completed | Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothel NCT03678350 | Roswell Park Cancer Institute | Phase 1 |
| Active Not Recruiting | A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC NCT04995523 | AstraZeneca | Phase 1 / Phase 2 |
| Enrolling By Invitation | Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage I NCT04762459 | Chinese Academy of Medical Sciences | Phase 3 |
| Terminated | Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma NCT04990479 | Nouscom SRL | Phase 1 |
| Recruiting | To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Re NCT04853342 | Allist Pharmaceuticals, Inc. | Phase 3 |
| Completed | Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programm NCT04738487 | Merck Sharp & Dohme LLC | Phase 3 |
| Withdrawn | An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) NCT03770299 | Bristol-Myers Squibb | Phase 2 |
| Recruiting | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) NCT04585750 | PMV Pharmaceuticals, Inc | Phase 1 / Phase 2 |
| Withdrawn | NEUWAVE Flexible Probe Study #2 NCT03713099 | Ethicon, Inc. | N/A |
| Completed | A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled NCT06282991 | Pfizer | — |
| Completed | Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns NCT04351334 | Pfizer | — |
| Terminated | Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced L NCT03735095 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Active Not Recruiting | DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cance NCT04042701 | Daiichi Sankyo | Phase 1 |
| Unknown | Osimertinib Resistance in Patients With Non-small-cell Lung Carcinoma That Have Progressed. NCT04737382 | The Netherlands Cancer Institute | N/A |
| Terminated | Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies NCT04000529 | Novartis Pharmaceuticals | Phase 1 |
| Terminated | A Safety Study of SGN-CD47M in Patients With Solid Tumors NCT03957096 | Seagen Inc. | Phase 1 |
| Completed | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tum NCT03849469 | Xencor, Inc. | Phase 1 |
| Completed | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) NCT03752398 | Xencor, Inc. | Phase 1 |
| Active Not Recruiting | A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC NCT02905591 | Joseph J. Cullen, MD, FACS | Phase 2 |
| Active Not Recruiting | Online Psychosocial Intervention in Improving Social Well-Being and Support in Women With Stage I-IV Non-small NCT03731585 | M.D. Anderson Cancer Center | N/A |
| Completed | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies NCT03590054 | Rahul Aggarwal | Phase 1 |
| Completed | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors NCT03517488 | Xencor, Inc. | Phase 1 |
| Terminated | NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung NCT03603652 | Ethicon, Inc. | N/A |
| Terminated | Bronchoscopy With Bronchoalveolar Lavage in Identifying Biomarkers of Response to Immune Checkpoint Inhibitors NCT02937402 | Vanderbilt-Ingram Cancer Center | N/A |
| Completed | Study of Nivolumab for Advanced Cancers in India NCT03444766 | Bristol-Myers Squibb | Phase 4 |
| Withdrawn | Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer NCT03408561 | University of Southern California | N/A |
| Terminated | Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Ca NCT03054038 | Vanderbilt-Ingram Cancer Center | Phase 1 |
| Completed | Patient Navigation for Lung Cancer Screening in an Urban Safety-Net System NCT02758054 | University of Texas Southwestern Medical Center | N/A |
| Completed | Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lu NCT03088540 | Regeneron Pharmaceuticals | Phase 3 |
| Completed | A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cance NCT02864251 | Bristol-Myers Squibb | Phase 3 |
| Completed | Anti PD-1 Neo-adjuvant Treatment for NSCLC NCT02938624 | Jair Bar, M.D., Ph.D. | Phase 1 |
| Completed | Neoadjuvant Pembrolizumab NCT02818920 | Neal Ready MD PhD | Phase 2 |
| Unknown | Efficacy-Safety-Immunogenicity Study of CBT124&EU-sourced Avastin® in Stage 4 NSCLC NCT02879097 | Cipla BioTec Pvt. Ltd. | Phase 3 |
| Completed | Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer. NCT02922777 | University of Texas Southwestern Medical Center | Phase 1 |
| Completed | Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alte NCT02795156 | SCRI Development Innovations, LLC | Phase 2 |
| Active Not Recruiting | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy NCT02432963 | City of Hope Medical Center | Phase 1 |
| Completed | N2 Lung Cancer Project: Neoadjuvant Treatment Followed Surgery Versus Chemoradiation NCT02966769 | Grupo de Investigación Clínica en Oncología Radioterapia | — |
| Completed | Evaluation of Tumor and Blood Immune Biomarkers in Resected Non-small Cell Lung Cancer NCT02848872 | Duke University | — |
| Terminated | A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers NCT02711345 | Novartis Pharmaceuticals | Phase 1 |
| Terminated | Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma in Non Small Cell Lun NCT02762877 | Genomic Health®, Inc. | — |
| Completed | Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First L NCT03950674 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Meta NCT02693080 | Stanford University | Phase 1 |
| Completed | Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First L NCT02578680 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Optical Biopsy for Thoracic Lymph Nodes. NCT02689050 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | — |
| Completed | Hypermetabolism in the Elderly Lung Cancer Patient NCT03141957 | University of Paris 5 - Rene Descartes | — |
| Unknown | The Value Of Circulating Tumor Cells In Patient With NSCLC In Postoperative Recurrence Monitoring NCT02647164 | GenoSaber | — |
| Withdrawn | Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors NCT02537561 | Washington University School of Medicine | Phase 1 |
| Unknown | Evaluation of FLT-PET and DWI-MRI in Patients With NSCLC Treated With a Platinum-based Doublet as Preoperative NCT02273271 | European Organisation for Research and Treatment of Cancer - EORTC | N/A |
| Terminated | IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases NCT02556593 | Sun Yat-sen University | Phase 2 |
| Completed | Phase I Trial Of IMRT Using A Contralateral Esophagus Sparing Technique (CEST) In Locally Advanced Lung Cancer NCT02394548 | Massachusetts General Hospital | N/A |
| Unknown | Anticancer Activity of Nicotinamide on Lung Cancer NCT02416739 | Il Yeong Park, Ph.D. | Phase 2 / Phase 3 |
| Terminated | Study of the Efficacy of SBRT on Unresectable Peripheral Primary Tumor NCT02400424 | Centre Leon Berard | N/A |
| Withdrawn | Combination of gp96-Ig Vaccine, Theophylline and Oxygen for the Treatment of Patients With Advanced, Relapsed NCT01799161 | Eckhard Podack | Phase 1 |
| Completed | Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non NCT02142738 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III NCT02186847 | NRG Oncology | Phase 2 |
| Completed | Use of [18]F-FDG on PET/CT as an Alternative Non-invasive Method for Staging of Lung Cancer NCT02664792 | Latin American Cooperative Oncology Group | N/A |
| Unknown | Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer NCT02151721 | Kanazawa University | Phase 1 |
| Terminated | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy NCT02062632 | Mayo Clinic | Phase 2 |
| Completed | A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non- NCT02039674 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Completed | Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous No NCT01999673 | Peregrine Pharmaceuticals | Phase 3 |
| Completed | A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors NCT02009449 | Eli Lilly and Company | Phase 1 |
| Completed | Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients NCT01941316 | Cancer Research and Biostatistics Clinical Trials Consortium | Phase 1 / Phase 2 |
| Completed | Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors NCT01999738 | Endocyte | Phase 1 |
| Completed | A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma NCT01801111 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Unknown | Clinical Trial: Effectiveness and Efficiency of Physical Exercise in Cancer Patients NCT01786122 | Basque Health Service | N/A |
| Terminated | Trial of RNActive®-Derived Cancer Vaccine and Local Radiation in in Stage IV Non Small Cell Lung Cancer (NSCLC NCT01915524 | CureVac | Phase 1 |
| Unknown | Risk-adapted Stereotactic Body Radiotherapy for Early Non-Small Cell Lung Cancer Using the VERO Stereotactic B NCT02224547 | Universitair Ziekenhuis Brussel | Phase 2 |
| Completed | Genotype-Driven Treatment of Advanced Non-small Cell Lung Cancer Based on mRNA Expression of ERCC1 & RRM1 as F NCT01648517 | Yonsei University | Phase 2 |
| Terminated | Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer NCT01383148 | Transgene | Phase 2 / Phase 3 |
| Completed | Assessment of 4D 18F-FDG PET-CT in Radiotherapy for Non Small Cell Lung Cancers NCT01421953 | University Hospital, Bordeaux | N/A |
| Completed | A Study in Non-Small Cell Lung Cancer NCT01232452 | Eli Lilly and Company | Phase 2 |
| Terminated | A Study of DS-2248 in Participants With Advanced Solid Tumors NCT01288430 | Daiichi Sankyo | Phase 1 |
| Completed | Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung Cancer NCT01255150 | National Cancer Institute (NCI) | — |
| Completed | Observing Patients With Palliative Asymptomatic Centrally Located Advanced Non-small Cell Lung Carcinoma (NSCL NCT01279408 | University Health Network, Toronto | — |
| Completed | Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib NCT01229150 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer NCT01185639 | Wake Forest University Health Sciences | N/A |
| Completed | Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib a NCT01167244 | Bristol-Myers Squibb | Phase 2 |
| Completed | Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung NCT01109524 | Eli Lilly and Company | Phase 2 |
| Unknown | Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma ( NCT01027676 | National Cancer Center, Korea | Phase 1 / Phase 2 |
| Terminated | Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lu NCT01090830 | Holy Cross Hospital, Florida | Phase 1 / Phase 2 |
| Completed | Molecular Imaging With Erlotinib and Bevacizumab NCT01047059 | University of Cologne | Phase 2 |
| Completed | Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non NCT00985855 | Institut de Cancérologie de la Loire | Phase 2 |
| Completed | Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Pr NCT01209520 | University of Miami | N/A |
| Completed | Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally A NCT00915005 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic NCT00890903 | Pierre Fabre Pharma GmbH | — |
| Completed | Biological Factors Predicting Response to Chemotherapy in Advanced Non Small Cell Lung Cancer NCT00864266 | European Lung Cancer Working Party | N/A |
| Completed | A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002) NCT00753415 | Merck Sharp & Dohme LLC | Phase 1 |
| Unknown | Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Meas NCT00759382 | European Lung Cancer Working Party | — |
| Withdrawn | A Study to Assess the Safety and Preliminary Efficacy of PT-523 in Patients With Advanced Non-Small Cell Lung NCT00112060 | Spectrum Pharmaceuticals, Inc | Phase 1 / Phase 2 |
| Completed | A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Pat NCT00600821 | Pfizer | Phase 2 |
| Completed | Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance NCT01836575 | Instituto Nacional de Cancer, Brazil | Phase 3 |
| Completed | Phase I Study of Vorinostat and Sorafenib in Advanced Cancer NCT00635791 | University of Colorado, Denver | Phase 1 |
| Completed | Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced N NCT00602030 | Syndax Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer NCT00540514 | Celgene | Phase 3 |
| Completed | Study About Preventive Treatment of Folliculitis Induced by Epidermal Growth Factor Receptor Inhibitors NCT00910676 | Centre Oscar Lambret | Phase 2 |
| Completed | Effect of All-trans Retinoic Acid With Chemotherapy Based in Paclitaxel and Cisplatin as First Line Treatment NCT01048645 | National Institute of Cancerología | Phase 2 |
| Terminated | Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer NCT00592007 | Lyudmila Bazhenova, M.D. | Phase 2 |
| Terminated | Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cance NCT00511576 | Mirati Therapeutics Inc. | Phase 1 |
| Terminated | Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Maligna NCT00565227 | University of Michigan Rogel Cancer Center | Phase 1 |
| Completed | Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC) NCT00444015 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Unknown | Protocol for Primary Fractionated Stereotactic Body Radiation Therapy for Stage T1 - T3N0 Non Small Cell Lung NCT00727350 | Universitair Ziekenhuis Brussel | Phase 2 |
| Terminated | Randomised Study of Concomitant Radiochemotherapy in Non-small Cell Lung Cancer NCT00633568 | European Lung Cancer Working Party | Phase 3 |
| Completed | SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients NCT00608868 | AstraZeneca | Phase 4 |
| Terminated | Lobectomy and Mediastinal Radiochemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer Responding to NCT00661011 | European Lung Cancer Working Party | Phase 2 |
| Completed | LUCY: A Study for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in Patients Previously Treated With Chem NCT00328588 | Astellas Pharma Inc | Phase 2 |
| Unknown | Concurrent Helical Tomotherapy With Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) NCT00379717 | Universitair Ziekenhuis Brussel | Phase 1 / Phase 2 |
| Completed | ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures NCT00404924 | Genzyme, a Sanofi Company | Phase 3 |
| Terminated | Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Ce NCT00365183 | Pharmacyclics LLC. | Phase 2 |
| Withdrawn | Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjec NCT00090675 | AstraZeneca | Phase 3 |
| Completed | The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer NCT00243347 | AstraZeneca | Phase 1 |
| Completed | Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer NCT00129844 | Pharmacyclics LLC. | Phase 2 |
| Completed | Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer NCT00124280 | Novartis Pharmaceuticals | Phase 2 |
| Unknown | Hypercoagulable Parameters as Predictors of Thrombotic Events and Prognosis in Patients With Advanced Non-Smal NCT00192829 | Rambam Health Care Campus | — |
| Completed | Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer NCT00111839 | EMD Serono | Phase 2 |
| Terminated | Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent C NCT00271323 | Sanofi | Phase 2 |
| Terminated | Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer NCT00232206 | Providence Health & Services | Phase 2 |
| Completed | Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer. NCT00105092 | Eli Lilly and Company | Phase 2 |
| Completed | A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell NCT00162318 | Eli Lilly and Company | Phase 1 |
| Completed | Post-Surgical Non-Small Cell Lung Cancer (NSCLC) Follow-up NCT00198341 | Intergroupe Francophone de Cancerologie Thoracique | N/A |
| Completed | Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non- NCT00112346 | Eli Lilly and Company | Phase 2 |
| Completed | ZD6474 Phase IIa Dose Finding Multicentre Study NCT00252746 | Genzyme, a Sanofi Company | Phase 2 |
| Completed | Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, NCT00100932 | Eisai Inc. | Phase 2 |
| Terminated | A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast NCT00126451 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Pat NCT00201825 | Tony Bekaii-Saab | Phase 2 |
| Completed | Safety Study of Individualised Radiation Dose Determination for Lung Cancer Patients. NCT00181545 | Maastricht Radiation Oncology | Phase 1 |
| Completed | Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Sm NCT00112294 | Eli Lilly and Company | Phase 3 |
| Completed | BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer NCT00098254 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small C NCT00102505 | Pharmacyclics LLC. | Phase 1 |
| Withdrawn | Celecoxib Treatment for Lung Cancer NCT00108186 | US Department of Veterans Affairs | Phase 1 |
| Completed | A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) NCT00091663 | Genentech, Inc. | Phase 3 |
| Completed | Positron Emission Tomography (PET) Imaging in Stage III Non-small Cell Lung Cancer (PET START Trial) NCT00136864 | Ontario Clinical Oncology Group (OCOG) | Phase 3 |
| Completed | FDG-PET to Investigate SGN-15 and Docetaxel in Patients With Advanced Non-Small Cell Lung Carcinoma NCT00086333 | Seagen Inc. | Phase 2 |
| Completed | A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Sma NCT00095225 | Genentech, Inc. | Phase 2 |
| Completed | Phase II Iressa Versus Vinorelbine (INVITE) NCT00256711 | AstraZeneca | Phase 2 |
| Completed | A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Local NCT00087711 | Eli Lilly and Company | Phase 3 |
| Completed | PET Imaging in Potentially Surgically Resectable Non-small Cell Lung Cancers NCT00136890 | Ontario Clinical Oncology Group (OCOG) | Phase 3 |
| Completed | Non-small Cell Lung Cancer Study US75 (Z-PACT) NCT00086268 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Study Comparing Short Infusion Vs. Fixed Dose of Cisplatin + Gemcitabine in Non Small Cell Lung Cancer. NCT00191620 | Eli Lilly and Company | Phase 2 |
| Completed | Iressa Versus Docetaxel (Taxotere) NCT00076388 | AstraZeneca | Phase 3 |
| Terminated | Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC NCT00234468 | AstraZeneca | Phase 3 |
| Completed | Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma NCT00078455 | Genzyme, a Sanofi Company | Phase 2 |
| Completed | Detection of Plasma DNA in Non Small Cell and Small Cell Lung Cancer Patients NCT00213798 | University Hospital, Strasbourg, France | N/A |
| Completed | Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis i NCT00081315 | MedImmune LLC | Phase 2 |
| Completed | Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer NCT00098085 | Agenus Inc. | Phase 2 |
| Completed | Study of an Early Change of a Chemotherapeutic Doublet Versus Four Cycles of Chemotherapy in Advanced Non Smal NCT00199758 | University Hospital, Limoges | Phase 2 |
| Completed | Trial to Evaluate Radiotherapy With or Without CBDCA in Elderly Patients With Non-Small Cell Lung Cancer (JCOG NCT00132665 | Japan Clinical Oncology Group | Phase 3 |
| Completed | Phase II Study of Celecoxib and Concurrent Radiotherapy in Stage II-III NSCLC NCT00181532 | Maastricht Radiation Oncology | Phase 2 |
| Completed | ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Canc NCT00056537 | Active Biotech AB | Phase 1 |
| Completed | Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients NCT00137800 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Chemoradiotherapy in Patients With Localised Lung Cancer NCT00193921 | Trans Tasman Radiation Oncology Group | Phase 2 |
| Completed | ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer NCT00252798 | AstraZeneca | Phase 1 |
| Completed | Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double NCT00148395 | Aktion Bronchialkarzinom e.V. | Phase 3 |
| Completed | Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concur NCT00037817 | National Cancer Institute (NCI) | Phase 1 |
| Completed | HI-CHART:Feasibility of High-Dose Accelerated Conformal Radiotherapy NCT00181506 | Maastricht Radiation Oncology | Phase 1 / Phase 2 |
| Terminated | Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20) NCT00310232 | Ontario Clinical Oncology Group (OCOG) | Phase 3 |
| Terminated | LIFE-Lung Bronchoscopy in Patients at Risk for Developing Lung Cancer NCT00260598 | University of Pittsburgh | Phase 2 |
| Completed | Study Evaluating EKB-569 in Advanced Non-Small Cell Lung Cancer NCT00067548 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 2 |
| Completed | Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer NCT00080340 | Telik | Phase 3 |
| No Longer Available | An Expanded Access Program for AM0010 (Pegilodecakin) NCT03554434 | Eli Lilly and Company | — |